The RayPilot® system for real-time electromagnetic positioning of the prostate during radiation therapy will be installed on the French cancer center, Centre Georges-François Leclerc (CGFL) in Dijon during the spring of 2014. It will be the first installation of RayPilot in France.
- Micropos and Qualimedis has signed an agreement with the Centre Georges-François Leclerc in Dijon, about to start using RayPilot in March 2014. The contract states that the clinic will evaluate RayPilot in the clinic's regular process for image-guided radiotherapy (IGRT) of prostate cancer and to examine the benefits of a tool for real-time positioning and additionally the upcoming dosimetry function says Pierre-Xavier Ribot, CEO of Qualimedis.
The RayPilot system has been in clinical use since 2010 and around 30 scientific papers, posters and oral presentations has been presented at scientific meetings and in literature such as the ESTRO, ASTRO, AAPM and The Green Journal. The latest poster was presented at the medical physicist congress, AIFM, in Turin in Italy recently, where Humanitas Gavazzeni in Bergamo have used the RayPilot system for prostate tracking and has registered prostate motion over 1,5 cm during the treatment. The Poster can be downloaded at:
An updated RayPilot tracking sensor with included in-situ dosimetry is scheduled for release in 2014 and CGFL in Dijon will be the first centre in France to be able to use the device that can both track and measure the administrated dose in the tumor region.
For further information contact:
Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-772 80 99
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish medical device start-up that was founded in 2003 as a result of four physicians’ long clinical experience in the therapeutic radiation oncology field (cancer treatment). The company has developed the RayPilot® system for increased precision in radiotherapy of prostate cancer. The RayPilot® system is an electromagnetic positioning system that initially enables real time position of the prostate for a fast and objective set-up and for continuous positioning during the treatment. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; a transmitter that is placed in the ROI, a receiving system that is placed directly on any existing treatment coach and software that continuously shows where the tumor is and where to beam. The transmitter is removed after the final treatment in order to enable MRI follow-up.